



## Hikma Pharmaceuticals PLC

### Voting Results of Extraordinary General Meeting

London, 19 February 2016 – Hikma Pharmaceuticals PLC (“**Hikma**” or the “**Company**”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, announced on 28 July 2015 that it had agreed terms to acquire Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from Boehringer Ingelheim (the “**Acquisition**”).

The Company is pleased to announce that, at the General Meeting held today, the resolutions (the “**Resolutions**”) in respect of the Acquisition were decided on a poll and passed as ordinary resolutions. Details of the Resolutions were set out in the combined prospectus and circular published on 22 January 2016 and posted to shareholders on 25 January 2016 (the “**Prospectus**”) and the supplementary prospectus and circular which was published and sent to shareholders on 11 February 2016. Completion of the Acquisition is expected to take place on 29 February 2016.

The total number of votes cast on the poll for each resolution is set out below.

	Resolution	For		Against		Votes withheld	Total votes cast
		Votes	%	Votes	%		
1.	Approving the transaction	157,068,100	99.98%	31,346	0.02%	491,344	157,099,446
2.	Granting the Directors authority to allot the Consideration Shares	157,078,102	99.99%	21,344	0.01%	491,344	157,099,446
3.	Approving the off-market purchase contract and off-market purchase by the Company of its own shares	157,049,321	99.97%	50,341	0.03%	491,128	157,099,662

Notes:

As at 19 February 2016, the Company's issued share capital was 199,385,501 ordinary shares of 10 pence each.

1. Votes withheld are not votes under English law and so have not been included in the calculation of the votes cast "For" or "Against" the Resolution.
2. Percentages are expressed as a proportion of the total votes cast and have been rounded to two decimal places.

Completion of the Acquisition remains subject to the satisfaction or waiver of certain other conditions, including the expiration of any HSR Act antitrust waiting period, set out in Part I of the Prospectus.

Capitalised terms used in this announcement have the meanings given to them in the Prospectus.

This announcement is made pursuant to the requirements of Listing Rule 9.6.18R. In accordance with Listing Rule 9.6.2R, two copies of the Resolutions will shortly be submitted to the National Storage Mechanism and will be available for inspection at [www.morningstar.co.uk/uk/NSM](http://www.morningstar.co.uk/uk/NSM).

The results of the General Meeting will shortly be available on the Company's website at [www.hikma.com](http://www.hikma.com).

**For further information please contact:**

**Hikma Pharmaceuticals PLC**

Peter Speirs +44 20 7399 2670  
Company Secretary

Susan Ringdal +44 20 7399 2670  
VP for Investor Relations and Strategy

**FTI Consulting**

Ben Atwell/ Matthew Cole +44 20 3727 1000

**About Hikma**

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of \$1,489 million and profit attributable to shareholders of \$278 million.